| |
|
New Gilead HCV Elimination Funding: HIV/HCV No Co-Infection (NoCo) Program: Micro-Elimination of HCV in
HIV-Infected and High-Risk HIV-Uninfected Populations
|
| |
| |
Download the PDF here
Through Medical Affairs, Gilead Sciences supports the research efforts of academic institutions, clinical investigators, community organizations and research networks to help inform the scientific community about barriers and facilitators of HCV elimination, including micro-elimination in people living with HIV. Gilead intends to support investigators focused on addressing the challenges associated with HCV elimination for individuals co-infected with HIV or in people at high risk for HIV infection, ie, HIV-negative men who have sex with men (MSM) on pre-exposure prophylaxis (PrEP). Many people living with HIV or on PrEP are linked and engaged in care. Thus, targeting micro-elimination of HCV in HIV-infected or high-risk HIV-uninfected individuals is a feasible and a more proximate short-term goal and a positive step toward more global HCV elimination.
Gilead will support projects with research grants of up to $600,000 each, with an emphasis on achieving geographic distribution across the globe. Successful proposals will demonstrate clear scientific objectives, defined timelines, a comprehensive operational plan and the potential to generate data that has relevance to the medical community and policy makers. Additional information about the NoCo Program is found in the downloadable Request for Applications (RFA) document available in the sidebar.
Key Dates & Program Specifics:
o Proposals will be initiated with a Letter of Intent (LOI), submitted to NoCo@gilead.com
o A LOI should be submitted using the templated provided in the side bar
o 03 July 2018: LOI submission window opens
o 30 August 2018: LOI submission window closes
Questions about the program or application process should be submitted to your local Gilead Medical Scientist or to NoCo@gilead.com
| |
| |
| |
|
|
|
